Skip to main content
Clinical Trials/NCT03435185
NCT03435185
Completed
Not Applicable

Greater Occipital and Supraorbital Nerve Blockade For The Preventive Treatment of Migraine

Dr. Lutfi Kirdar Kartal Training and Research Hospital0 sites103 target enrollmentSeptember 1, 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Migraine Disorders
Sponsor
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Enrollment
103
Primary Endpoint
Change of Frequency of Headache
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The investigators aimed to evaluate the efficacy of greater occipital nerve and supraorbital nerve blockade with local anesthetics for the preventive treatment of migraine without aura.

Detailed Description

A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to GON and SON in the blockade patients. Placebo patients received 2 ml 0.9% saline in the same way. Patients were blinded to kind of injection.

Registry
clinicaltrials.gov
Start Date
September 1, 2014
End Date
June 1, 2016
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Responsible Party
Principal Investigator
Principal Investigator

Cem Bölük

Medical Doctor

Dr. Lutfi Kirdar Kartal Training and Research Hospital

Eligibility Criteria

Inclusion Criteria

  • Lack of benefits 1 year from preventive treatment or intolerance to their treatments.
  • 18 ≥ years old
  • Migraine without aura for more than 1 year, minimum of two or more migraine attacks per month.

Exclusion Criteria

  • Patients with any chronic illness, medication overuse headache, a history of cranial and cervical surgery
  • Allergies to local anesthetics
  • Hemorrhagic diathesis
  • Alcohol or drug abuse

Outcomes

Primary Outcomes

Change of Frequency of Headache

Time Frame: Patients were followed up from baseline to 2 months after first injection.

Number of headache days in a month. Scores from both months were averaged. Minimum=0 Maximum=30. Lower scores mean a better outcome.

Change of Severity of Headache

Time Frame: Patients were followed up for 2 months from baseline after first injection.

Mean visual analog scale (VAS) scores. Scores from both months were avareged. Minimum=0 Maximum=10. Lower scores mean a better outcome

Similar Trials